LEO 124249

Drug Profile

LEO 124249

Alternative Names: LEO124249

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LEO Pharma
  • Class Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alopecia areata; Eczema; Inverse psoriasis

Most Recent Events

  • 01 Nov 2017 LEO Pharma plans a phase II trial for Alopecia areata in 2017 (EudraCT2017-002720-24) (NCT03325296)
  • 30 Oct 2017 Phase-II clinical trials in Alopecia areata in Denmark (Topical) (NCT03325296) (EudraCT2017-002720-24)
  • 01 Dec 2016 LEO Pharma completes a phase-II trial in Alopecia areata in USA (Topical) (NCT02561585)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top